Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Trends Cancer. 2023 Oct;9(10):840-854. doi: 10.1016/j.trecan.2023.06.009. Epub 2023 Jul 11.
The field of metastatic prostate cancer (mPCa) has seen unprecedented therapeutic advances in the past decade. In the past 2 years, recent approvals include the triplet therapy regimens of androgen deprivation therapy (ADT), docetaxel, and an androgen receptor (AR) pathway inhibitor (ARPI) in the castration-sensitive setting and lutetium-177 vipivotide tetraxetan (Lu-PSMA-617) and the combination of poly(ADP) ribose polymerase (PARP) inhibitors (PARPis) and ARPIs in the castration-resistant setting. With many agents currently undergoing investigation in registration trials, the therapeutic armamentarium will expand rapidly, making treatment selection and sequencing challenging. Herein, we review the landmark clinical trials ongoing or reported in the past 2 years, discuss the optimal approach to treatment selection, and provide insight into future directions.
过去十年，转移性前列腺癌（mPCa）领域取得了前所未有的治疗进展。在过去的 2 年中，最近批准的方案包括在去势敏感环境中的雄激素剥夺治疗（ADT）、多西他赛和雄激素受体（AR）通路抑制剂（ARPI）三联疗法，以及镥-177 放射性核素标记肽（Lu-PSMA-617）和聚（ADP-核糖）聚合酶（PARP）抑制剂（PARPi）与 ARPIs 的联合方案在去势抵抗性环境中。随着许多药物目前正在注册试验中进行研究，治疗手段将迅速扩展，这使得治疗选择和排序具有挑战性。在此，我们回顾了过去 2 年内正在进行或报告的具有里程碑意义的临床试验，讨论了最佳的治疗选择方法，并对未来的方向提供了一些见解。
